Developing RNAi Therapeutics (Part I)
An interview with Patrick Lu, Founder and CEO of Sirnaomics, Inc.
on September 14, 2009
Essinova host BeiBei Song interviewed Patrick Lu, Ph.D., Founder and CEO of Sirnaomics, Inc, about the science and business of developing RNAi therapeutics during the IBC Oligonucleotide Therapeutics conference in Boston.
In this segment, Dr. Lu comments on the potential of RNAi therapeutics as the "Next Big Thing" in drug discovery and development, the scientific challenges of realizing such potential, and the latest technological development in the field as evidenced in the meeting.
Tags: RNAi, siRNA, miRNA, oligonucleotides, Sirnaomics, Patrick Lu, IBC, DDD